Across jurisdictions, legal changes are impacting the pharmaceutical industry and how drug companies handle large and small patent litigation cases. Asia IP contacted Finnegan partner John D. Livingstone for his thoughts on how to handle high-profile cases.
Livingstone said, “In high-profile cases, one should plan from the start to manage the expectations of the client and the media. For example, even if the case appears strong, public comments should be tempered by the realization that the case might not turn out as well as expected because of facts or issues not yet uncovered. Thus, overly optimistic comments should be avoided in most instances.”
